AFT Pharma (ASX:AFP) to initiate further studies on Maxigesic IV

2 min read | September 02, 2022 11:59 AM AEST | By Ritwika

Google News:

AFT Pharma (ASX:AFP) to initiate further studies on Maxigesic IV — Image source: © Akesin | Megapixl.com

Recent News

ASX Technology Leaders on ASX 200 Revenue and Scale

Can Hidden ASX Names Become Tomorrow’s Market Leaders?

How Are ASX 300 Gold Miners Responding to Record Gold?

ASX Gold Mining Outlook on ASX 100 Costs and Cash Flow

Make Kalkine Media
My Trusted Source

Highlights:

Both the developers of Maxigesic IV drug, AFT Pharmaceuticals and Hyloris Pharmaceuticals, will be conducting further studies on the drug’s packaging before filing for the US FDA registration.

These studies will primarily reveal information on extractable and leachable from the packaging of Maxigesic IV, as requested by FDA in July 2022.

Maxigesic IV is a combination of Paracetamol and Ibuprofen, used to treat post-operative pain.

Leading healthcare giant AFT Pharmaceuticals Limited (ASX:AFP) said that it will conduct further studies before filing the US Food & Drug Administration (FDA) registration for its pain relief medicine, Maxigesic IV.

Maxigesic IV is a pain relief drug that will primarily be used to treat post-operative pain. The drug consists of 1000mg paracetamol and 300mg ibuprofen solution for infusion.

Both AFT Pharmaceuticals and Hyloris Pharmaceuticals have collaborated to develop this drug. Maxigesic has secured a license in more than 100 countries across the world. The drug has also been registered in 41 countries and launched in 10 countries, including Australia, France, Germany, Indonesia and Korea.

Update on AFT Pharmaceutical’s Maxigesic IV registration by FDA:

Both the development partners of the pain relief drug, AFT and Hyloris Pharmaceuticals, are planning to initiate further studies that will provide more information to FDA related to Maxigesic IV’s packaging as per FDA’s July 2022 studies.

These studies are likely to provide further detailed information on extractable and leachable from the packaging of Maxigesic IV. The studies are expected to begin this year itself and are scheduled to get completed in the new year. Followed by the completion of the studies, AFT will be filing for the registration of Maxigesic IV.

Recent developments within AFT:

On 1 September 2022, AFT announced that it had signed up for an agreement with Massey Ventures. The agreement will allow AFT to license intellectual property (IP) to allow the development of a topical treatment for strawberry birthmarks in children.

Massey Ventures is the commercialisation arm of Massey University and the Gillies McIndoe Research Institute.

Meanwhile, the shares of AFT Pharmaceuticals were spotted trading last at AU$2.9 apiece on ASX.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.